Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
6
75%
Ph phase_3
1
13%
Ph phase_1
1
13%

Phase Distribution

1

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
6(75.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(3)
Terminated(2)
Other(3)

Detailed Status

unknown3
Completed3
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 26 (75.0%)
Phase 31 (12.5%)

Trials by Status

withdrawn113%
unknown338%
terminated113%
completed338%

Recent Activity

0 active trials
Showing 5 of 8
unknownphase_2

Role of Perhexiline in Hypertrophic Cardiomyopathy

NCT04426578
terminatedphase_2

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

NCT02862600
withdrawnphase_3

Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure

NCT02431221
completedphase_2

Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome

NCT00839228
completedphase_2

Metabolic Manipulation in Chronic Heart Failure

NCT00841139
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04426578Phase 2

Role of Perhexiline in Hypertrophic Cardiomyopathy

Unknown
NCT02862600Phase 2

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Terminated
NCT02431221Phase 3

Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure

Withdrawn
NCT00839228Phase 2

Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome

Completed
NCT00841139Phase 2

Metabolic Manipulation in Chronic Heart Failure

Completed
NCT00989508Phase 2

Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy

Unknown
NCT00845364Phase 2

Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery

Completed
NCT00628056Phase 1

Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8